FAPi PET scan for pancreatic cancer
Part of Cancer, Digestive system, Hormones & metabolism clinical trials.
This trial uses a special PET scan (FAPi PET) to see if it can help spot pancreatic ductal adenocarcinoma better than standard scans. It may offer a more precise way to check the extent of the disease.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older.
- You must have a confirmed diagnosis of pancreatic ductal adenocarcinoma (from a biopsy).
- You must be willing to take part in the study.
- You cannot have another active cancer.
- You cannot be pregnant or breastfeeding.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial uses a special imaging scan called FAPI-PET to help doctors better diagnose pancreatic cancer. If you are suspected of having pancreatic cancer or a recurrence, this study may help confirm or clarify your diagnosis.
This study tests a new type of PET scan that uses a radioactive tracer called FAPI-74 to find cancer spread in people with pancreatic cancer. The goal is to see if this scan can help doctors better plan treatment.
This trial tests a new type of PET scan that uses a special tracer (FAPI) to get clearer images of pancreatic cancer. The goal is to find cancer earlier and better plan surgery or treatment.
This trial uses a special PET scan (68Ga-FAPi-46) to see how breast cancer interacts with nearby cells. It may help doctors understand your tumor better and guide treatment decisions, especially if you are planning surgery or chemotherapy before surgery.
This trial tests a new imaging method called FAPI-PET to see if it can better detect pancreatic and bile duct cancers at an early stage. It may help doctors decide on the best treatment plan for you.
This trial tests a special imaging scan (a PET/CT with a tracer called 68Ga-FAPI-46) to look at “cancer-support” cells in people with localized pancreatic ductal adenocarcinoma. It may help doctors better understand the tumor and how it responds before surgery after initial treatment.
Hear when a new Pancreatic cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.